{"prompt": "['Alliance A171601', 'require minimal additional resource allocation. 43 The L3 landmark from cross-sectional', 'imaging has been identified as the strongest predictor of whole body fat and fat-free mass', 'when compared to dual-energy x-ray absorptiometry (DXA). 43 The advantage of using', 'advanced imaging modalities, such as CT imaging, is the ability to provide additional', 'qualitative measurements of muscle and fat beyond purely quantitative measures 44', '1.6', 'Quality of Life Questionnaires: EuroQol 5D 3L and EQ Visual Analog Scale (EQ VAS)', 'In addition to the reporting of symptoms, understanding how quality of life may be affected by', 'palbociclib and hormonal therapy in the metastatic setting in older patients has not been', 'evaluated previously and will add important information to this study. The EQ-5D (Appendix', 'V) is a measure of health status for use in evaluating health and healthcare. The EQ-5D-3L is', 'comprised of 2 pages: the EQ-5D descriptive system (page 1) and the EQ visual analogue scale', '(EQ VAS) (page 2). It provides a simple descriptive profile of five functional dimensions:', 'mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It generates a', 'single index value for health status on which full health is assigned a value of 1 and death a', 'value of 0. Thus, the index can be used to obtain a utility for these dimensions for use in', 'economic analyses. The EQ-5D has been specially designed to complement other quality of life', 'measures such as the SF-36, or cancer-specific measures. Each dimension has three levels', \"designated simply as 'no problem', 'some problem', or extreme problem', with patients checking\", 'the level most descriptive of their current level of function on each dimension. Five dimensions,', 'each with three levels, yield 243 possible distinct health states comprising the classification', 'system. The classification system has been assigned different standardized scores derived', 'through population-based samples of respondents who assign values to subsets of the 243 states', 'using the anchoring labels noted above. For example, health state 11212 represents a patient', 'who indicates some problems on the usual activities and anxiety/depression dimensions. A set', 'of valuation weights has thus been derived from a U.S. sample. 45 The Agency for Healthcare', 'Research and Quality has funded a study to develop definitive weights. EQ-5D is designed for', 'self-completion by patients and has been used extensively in mailed surveys. It is cognitively', 'simple, taking no more than a few minutes to complete.', '1.7', 'PRO-CTCAE', 'We will evaluate how well symptoms reported by patients correlate/agree with those compared', 'to what is reported in clinic using traditional AE evaluations.', 'Patient-reported outcomes (PRO) are an important part of new drug evaluation and may play a', 'role in regulatory approval of novel agents in oncology 46 PROs can be the consequences of', 'disease and/or its treatment as reported by the patient. PROs are evaluated through the use of', 'questionnaires developed to assess topics a patient can report about his or her own health and', 'are often completed electronically. This includes symptoms, physical functioning, and mental', 'health.', 'The current standard mechanism for reporting toxicities in cancer research is clinician-only', 'reporting using items from the National Cancer Institute (NCI) CTCAEs. In multiple studies,', 'PRO measures have improved the predictive accuracy of clinician CTCAE reporting. In a', \"prospective study including lung cancer patients' PRO measurements of toxicities better\", \"reflected patients' underlying state and functional status than clinician's evaluation 47 Although\", 'PROs have been well validated 48,49,50,51 these examinations have been minimally evaluated for', 'feasibility and accuracy in an older patient group and will meaningfully add to the data collection', 'on this study.', '12', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', 'We will focus our PROs on side effects most commonly reported in prior studies with', 'palbociclib and hormonal therapy and which of are of most interest, including all symptoms', 'listed in Appendix VI.', 'All surveys will be given to patients on paper, at the same time points as in-clinic evaluations', 'through cycle 6, unless patients come off study prior to cycle 6. We will use the PRO-CTCAE', 'items developed by the National Cancer Institute in order to allow patients to self-report the', 'above symptomatic adverse events. The primary purpose of the inclusion of PRO-CTCAE is to', 'evaluate the performance and agreement of patient-reported outcomes with those collected as', 'linician-reported CTCAEs.', '2.0', 'OBJECTIVES', '2.1', 'Primary Objective', 'To estimate the safety and tolerability (adverse event rate) of the combination of palbocic lib and', 'letrozole or fulvestrant in adults age 70 or older with estrogen receptor-positive, HER2-negative', 'metastatic breast cancer.', '2.2', 'Secondary objectives', '2.2.1 To describe the full toxicity profile inc cluding all grade 2 and higher adverse events (per NCI', 'CTCAE v.5.0), specifically estimating the rate of grade 2 and higher myelosuppression', '(neutropenia, leukopenia, thrombocytopenia, and anemia), neutropenic fever, GI side effects', '(nausea, diarrhea, decreased appetite, vomiting, mucositis-oral), fatigue, neuropathy, and', 'thromboembolism.', '2.2.2 To describe rates of dose reductions, dose holds, and hospitalizations.', '2.2.3 To estimate median time to treatment failure, including progression free survival and overall', 'survival.', '2.2.4 To estimate the rate of adherence to palbociclib, letrozole and fulvestrant.', '2.2.5 To explore factors other than chronologic age that can affect toxic ity rates as identified using', 'a cancer-specific geriatric assessment.', '2.2.6 To describe the results of the Was It Worth It (WIWI) Questionnaire and the Overall', 'Treatment Utility (OTU).', '2.2.7 To determine the degree of agreement between patient-reported AEs using PRO-CTCAE', 'measures and those reported using traditional collections for AEs.', '2.2.8 Toexamine the association between sarc openia and the development of toxicity and adverse', 'events.', '2.3', 'Correlative science objectives', '2.3.1 To explore the association between baseline chronic inflammatory mediator levels and', 'development of adverse events.', '2.3.2 To explore the association between baseline chronic inflammatory mediator levels and', 'treatment modification.', '2.3.3 To explore the association between baseline chronic inflammatory mediator levels and', 'baseline physical function as assessed by the cancer-specific geriatric assessment.', '13', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}